Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial


Marso S. P., Poulter N. R., Nissen S. E., Nauck M. A., Zinman B., Daniels G. H., ...More

AMERICAN HEART JOURNAL, vol.166, no.5, pp.823-835, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 166 Issue: 5
  • Publication Date: 2013
  • Doi Number: 10.1016/j.ahj.2013.07.012
  • Journal Name: AMERICAN HEART JOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.823-835
  • Akdeniz University Affiliated: No

Abstract

Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk for a broad range of adverse cardiovascular outcomes including coronary heart disease, stroke, and cardiovascular death. Liraglutide is a human glucagon-like peptide receptor analog approved for use in patients with type 2 diabetes mellitus (T2DM).